U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C19H22O2.C7H17NO5
Molecular Weight 477.5904
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VEDAPROFEN MEGLUMINE

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(C(O)=O)C1=C2C=CC=CC2=C(C=C1)C3CCCCC3

InChI

InChIKey=SGAJMCQBAWHKKC-WZTVWXICSA-N
InChI=1S/C19H22O2.C7H17NO5/c1-13(19(20)21)15-11-12-16(14-7-3-2-4-8-14)18-10-6-5-9-17(15)18;1-8-2-4(10)6(12)7(13)5(11)3-9/h5-6,9-14H,2-4,7-8H2,1H3,(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula C7H17NO5
Molecular Weight 195.2136
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C19H22O2
Molecular Weight 282.3768
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O19183
Gene ID: 791253.0
Gene Symbol: PTGS2
Target Organism: Equus caballus (Horse)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
QUADRISOL

Approved Use

Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).

Launch Date

1997
PubMed

PubMed

TitleDatePubMed
Treatment of persistent mating-induced endometritis in mares with the non-steroid anti-inflammatory drug vedaprofen.
2010-12
Practical experience with the treatment of recipient mares with a non-steroidal anti-inflammatory drug in an equine embryo transfer programme.
2010-12
Analgesic efficacy of perioperative use of vedaprofen, tramadol or their combination in cats undergoing ovariohysterectomy.
2009-06
Perioperative administration of vedaprofen, tramadol or their combination does not interfere with platelet aggregation, bleeding time and biochemical variables in cats.
2009-06
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
2008-02
Vedaprofen therapy in cats with upper respiratory tract infection or following ovariohysterectomy.
2007-02
Influence of vedaprofen (Quadrisol) on quality and freezability of stallion semen.
2005-11
The pharmacokinetics of vedaprofen and its enantiomers in dogs after single and multiple dosing.
2005-06
Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation.
2002-05

Sample Use Guides

Twice daily administration. An initial dose of 2 mg/kg (2.0 ml/100 kg) is followed by a maintenance dose of 1 mg/kg (1.0 ml/100 kg) given every 12 hours. Treatment can be continued for a maximum of 14 consecutive days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:38:58 GMT 2025
Edited
by admin
on Mon Mar 31 18:38:58 GMT 2025
Record UNII
S154JX9N3H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VEDAPROFEN MEGLUMINE
Common Name English
1-NAPHTHALENEACETIC ACID, 4-CYCLOHEXYL-.ALPHA.-METHYL-, COMPD. WITH D-1-DEOXY-1-(METHYLAMINO)GLUCITOL
Preferred Name English
Code System Code Type Description
SMS_ID
300000023674
Created by admin on Mon Mar 31 18:38:58 GMT 2025 , Edited by admin on Mon Mar 31 18:38:58 GMT 2025
PRIMARY
FDA UNII
S154JX9N3H
Created by admin on Mon Mar 31 18:38:58 GMT 2025 , Edited by admin on Mon Mar 31 18:38:58 GMT 2025
PRIMARY
PUBCHEM
139033180
Created by admin on Mon Mar 31 18:38:58 GMT 2025 , Edited by admin on Mon Mar 31 18:38:58 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY